Skip to main content
Clinical Trials/KCT0008312
KCT0008312
Completed
未知

The effects of extracorporeal blood purification (oXiris®) in patients with cardiogenic shock requiring VA-ECMO: A prospective, open-label, randomized controlled pilot study

Samsung Medical Center0 sites40 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Symptoms, signs and abnormal clinical and laboratory findings, NEC
Sponsor
Samsung Medical Center
Enrollment
40
Status
Completed
Last Updated
last year

Overview

Brief Summary

In this prospective, randomized pilot study of patients with CS requiring V-A ECMO, we investigated the efficacy of extracorporeal endotoxin and cytokine adsorption using oXiris. Our key findings can be summarized as follows: 1) the primary outcome of endotoxin levels at 48 hours did not significantly differ between the oXiris and control groups; 2) time-dependent analysis revealed significant reductions in inflammatory markers, particularly GDF-15 and IL-6, in the oXiris group at 24, 48 hours, and 7 days post-intervention; 3) hemodynamic parameters showed improvement in the oXiris group, with significant decreases in VIS and lactate levels, especially at 24 and 48 hours post-intervention; 4) ECMO weaning success, duration of ECMO support, and mortality rates were not significantly different between the groups.

Registry
who.int
Start Date
TBD
End Date
April 30, 2024
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with more than 18 years old
  • 2\. CS is defined as the presence of the following:
  • 2\-1\) Systolic blood pressure is less than 90 mmHg for more than 30
  • minutes despite the fluid therapy, or the use of pressure boosting agents
  • to maintain the systolic blood pressure more than 90 mmHg.
  • 2\-2\) Peripheral hypoperfusion (cold skin, urine less than 30 cc per
  • hour, impaired consciousness, lactate \=2\.0 mmol/l) or a person with
  • pulmonary edema.
  • 2\-3\) Causes of CS include ischemic (acute myocardial infarction
  • or ischemic cardiomyopathy, shock during percutaneous coronary

Exclusion Criteria

  • 1\. The patient or representative does not agree to the study
  • 2\. Pregnant women
  • 3\. Body weight under 30 kg
  • 4\. Heparin allergy
  • 5\. Other causes except for CS: septic shock, cardiac arrest by serious
  • ventricular arrhythmia mot related to the myocardial ischemia or heart
  • 6\. Shock with unwitnessed cardiac arrest outside the hospital
  • 7\. Severe non\-cardiac morbidity with expected survival less than 6 months (malignancy, respiratory failure)
  • 8\. Suspicious of brain death
  • 9\. Those who refused active treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials